[Glucocorticoid-induced osteoporosis. Occurrence, prophylaxis and treatment].
Vestergaard
Peter
P
Arhus Universitetshospital, Arhus Sygehus, Medicinsk Endokrinologisk Afdeling C. p-vest@post4.tele.dk
Laursen
Lars C
LC
Schwarz
Peter
P
Brixen
Kim
K
D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000008:administration & dosage; D002118:Calcium / Q000008:administration & dosage / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D008297:Male; D010006:Osteoblasts / Q000187:drug effects; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D012307:Risk Factors; D019379:Teriparatide / Q000008:administration & dosage; D014807:Vitamin D / Q000008:administration & dosage
D004164:Diphosphonates; D020847:Estrogen Receptor Modulators; D004967:Estrogens; D005938:Glucocorticoids; D019379:Teriparatide; D014807:Vitamin D; D002116:Calcitonin; D002118:Calcium